


Express Mail Label No. EV 956474505 US Dated: July 6, 2007

Docket No.: AVZ-001CPUSCN2RCE
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor Patent Application of:
Rima Kaddurah-Daouk *et al.*

Application No.: 10/718,765

Confirmation No.: 1461

Filed: November 21, 2003

Art Unit: 1639

For: USE OF CREATINE OR CREATINE
ANALOGS FOR THE TREATMENT OF
DISEASES OF THE NERVOUS SYSTEM

Examiner: J. S. Lundgren

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicants have not submitted a copy of the cited U.S. patent in accordance with 37 CFR 1.98(a)(2)(ii). Applicants submit herewith copies of foreign patents and non-patent references in accordance with 37 CFR 1.98(a)(2).

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.


This Information Disclosure Statement, pursuant to 37 CFR 1.114(c), accompanies the Request for Continued Examination (37 CFR 1.114) submitted herewith.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. AVZ-001CPUSCN2RCE.

Dated: July 6, 2007

CMS/SMW/mch

Respectfully submitted,

By 

Cynthia M. Soroos

Registration No.: 53,623

LAHIVE & COCKFIELD, LLP


One Post Office Square

Boston, Massachusetts 02109-2127

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/718,765-Conf. #1461
				Filing Date	November 21, 2003
				First Named Inventor	Rima KADDURAH-DAOUK
				Art Unit	1639
				Examiner Name	J. S. Lundgren
Sheet	1	of	1	Attorney Docket Number	AVZ-001CPUSCN2RCE

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-4,788,179	11-29-1988	Flohe et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO-92/14697-A1	09-03-1992	Cambridge Neuroscience, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	C1	Fitch, Coy D. et al., "A Study of Creatine Metabolism in Diseases Causing Muscle Wasting," <i>Journal of Clinical Investigation</i> , Vol. 43(3):444-452 (1964)			
	C2	Hirst, Marion et al., "Creatine and Rigidity," <i>Quarterly Journal of Medicine</i> , No. 83, pp. 401-418 (1928)			
	C3	Pettegrew, Jay W. et al., "Alterations of Cerebral Metabolism in Probable Alzheimer's Disease: A Preliminary Study," <i>Neurobiology of Aging</i> , Vol. 15(1):117-132 (1994)			
	C4	Reinhold, John G. et al., "The Chemical Composition of Voluntary Muscle in Muscle Disease: A Comparison of Progressive Muscular Dystrophy with Other Diseases Together with a Study of Effects of Glycine and Creatine Therapy," <i>J. Clin. Invest.</i> , Vol. 17(4):377-383 (1938)			
	C5	Vis, J.C. et al., "The mitochondrial toxin 3-nitropropionic acid induces differential expression patterns of apoptosis-related markers in rat striatum," <i>Neuropathology and Applied Neurobiology</i> , Vol. 27:68-76 (2001)			
	C6	Woznicki, Dennis T. et al., "Utilization of Cyclocreatine Phosphate, an Analogue of Creatine Phosphate, by Mouse Brain During Ischemia and Its Sparing Action on Brain Energy Reserves," <i>Journal of Neurochemistry</i> , Vol. 34(5):1247-1253 (1980)			
	C7	European Search Report for Application No. 06011215.8-2107, dated September 18, 2006			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--